The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial management, with a focus on advancing Alzheimer's treatments. However, the operational loss was a noted concern.

Company Guidance

During the Acumen Pharma Third Quarter 2025 Conference Call, the company provided detailed guidance on its ongoing programs and financial outlook. The ALTITUDE-AD Phase II trial is advancing well, with 542 participants, and the company is on track to release top line results by late 2026. The trial focuses on the efficacy and safety of sabirnetug, a monoclonal antibody targeting synaptotoxic A-beta oligomers. In addition, Acumen highlighted the progress of its Enhanced Brain Delivery (EBD) program, in collaboration with JCR Pharmaceuticals, which aims to improve treatment outcomes by pairing A-beta oligomer-directed antibodies with blood-brain barrier carrier technology. Financially, the company reported $136.1 million in cash and marketable securities as of September 30, 2025, which is expected to fund operations into early 2027. R&D expenses for the quarter were $22 million, while G&A expenses were $4.5 million, leading to a net loss of $26.5 million. The company remains optimistic about its strategic initiatives and the potential to deliver next-generation treatments for Alzheimer’s disease.

Progress in Phase II ALTITUDE-AD Trial

The ALTITUDE-AD trial is examining sabirnetug, a humanized monoclonal antibody. Participants are completing the placebo-controlled phase and moving into the open-label extension. Top line results are expected in late 2026.

Strategic Collaboration with JCR Pharmaceuticals

Acumen announced a collaboration with JCR Pharmaceuticals to develop Alzheimer's treatments using A-beta oligomer selective antibodies with JCR's blood-brain barrier technology.

Financial Position and Cost Management

Acumen reported $136.1 million in cash and securities, supporting activities into early 2027. R&D and G&A expenses decreased due to reduced CRO costs and lower legal and accounting fees.

Addition of Dr. George Golumbeski

Dr. George Golumbeski, with over 30 years of biotechnology experience, joined the board as Chairman, enhancing strategic initiatives and business development efforts.

Acumen Pharmaceuticals (ABOS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 30, 2026	2025 (Q4)	-0.47 / -	-0.62	―	―	―
Nov 12, 2025	2025 (Q3)	-0.60 / -0.44	-0.5	12.00% (+0.06)	―
Aug 12, 2025	2025 (Q2)	-0.49 / -0.68	-0.34	-100.00% (-0.34)	―
May 13, 2025	2025 (Q1)	-0.73 / -0.48	-0.25	-92.00% (-0.23)
Mar 27, 2025	2024 (Q4)	-0.51 / -0.62	-0.28	-121.43% (-0.34)
Nov 12, 2024	2024 (Q3)	-0.36 / -0.50	-0.24	-108.33% (-0.26)
Aug 13, 2024	2024 (Q2)	-0.28 / -0.34	-0.28	-21.43% (-0.06)
May 14, 2024	2024 (Q1)	-0.26 / -0.25	-0.28	10.71% (+0.03)	―
Mar 26, 2024	2023 (Q4)	-0.27 / -0.28	-0.32	12.50% (+0.04)	―
Nov 13, 2023	2023 (Q3)	-0.26 / -0.24	-0.26	7.69% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABOS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2025	$1.97	$1.95	-1.02%
Aug 12, 2025	$1.42	$1.26	-11.27%
May 13, 2025	$1.05	$1.05	0.00%
Mar 27, 2025	$1.16	$1.23	+6.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Acumen Pharmaceuticals (ABOS) report earnings?

Acumen Pharmaceuticals (ABOS) is schdueled to report earning on Mar 30, 2026, After Close (Confirmed).

What is Acumen Pharmaceuticals (ABOS) earnings time?

Acumen Pharmaceuticals (ABOS) earnings time is at Mar 30, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABOS EPS forecast?

ABOS EPS forecast for the fiscal quarter 2025 (Q4) is -0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing